This study is for people with heart disease, chronic kidney disease, and inflammation. It tests if a new medicine called ziltivekimab can lower the risk of heart problems, like heart attacks or strokes. Ziltivekimab is not available yet and is still being tested. Participants will be randomly given either ziltivekimab or a placebo (a dummy medicine) with equal chances. The medicine is given by a monthly injection using a pre-filled syringe.

The study can last up to 4 years, and participants will need to visit the clinic about 20 times. They will have blood and urine tests at most visits and heart checks using sound waves (echocardiography) and electrodes (electrocardiogram).

Women who are pregnant, breast-feeding, or planning to get pregnant cannot join.

• Study Duration: Up to 4 years with 20 clinic visits.
• Injections: Monthly using a pre-filled syringe.
• Eligibility: Must have certain heart or kidney conditions and inflammation.